Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$5.44 +0.4%	$5.44	$2.37 ▼ $5.72	$1.22B	2.53	704,959 shs	353,942 shs
LRMR Larimar Therapeutics	$3.91 +6.0%	$3.38	$1.61 ▼ $9.50	$305.45M	0.93	1.83 million shs	1.42 million shs
PAHC Phibro Animal Health	$32.46 +2.9%	$28.31	$16.16 ▼ $32.95	$1.28B	0.8	251,943 shs	194,402 shs
XERS Xeris Biopharma	$7.75 +2.1%	$5.53	$2.48 ▼ $7.79	$1.23B	0.65	3.33 million shs	1.70 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	-0.55%	-1.63%	-0.18%	+32.52%	+63.25%
LRMR Larimar Therapeutics	-2.12%	-13.38%	+9.17%	+97.33%	-54.67%
PAHC Phibro Animal Health	+1.32%	+3.21%	+7.94%	+35.76%	+70.91%
XERS Xeris Biopharma	+0.26%	+3.97%	+48.24%	+57.14%	+167.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVAC CureVac	4.7153 of 5 stars	4.1	5.0	0.0	4.9	2.3	0.0	1.3
LRMR Larimar Therapeutics	2.2639 of 5 stars	3.6	1.0	0.0	0.0	2.0	3.3	0.0
PAHC Phibro Animal Health	3.6202 of 5 stars	0.9	2.0	2.5	1.1	2.6	3.3	2.5
XERS Xeris Biopharma	3.4373 of 5 stars	1.4	3.0	0.0	4.2	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	2.20	Hold	$6.83	25.50% Upside
LRMR Larimar Therapeutics	3.10	Buy	$18.43	370.72% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-24.99% Downside
XERS Xeris Biopharma	2.83	Moderate Buy	$7.08	-8.54% Downside

Current Analyst Ratings Breakdown

Latest LRMR, PAHC, XERS, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	XERS Xeris Biopharma	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $9.00
8/15/2025	LRMR Larimar Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $18.00
8/12/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$579.18M	2.11	$0.87 per share	6.24	$2.97 per share	1.83
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.45 per share	N/A
PAHC Phibro Animal Health	$1.19B	1.11	$2.21 per share	14.73	$6.34 per share	5.13
XERS Xeris Biopharma	$246.03M	5.08	N/A	N/A	($0.12) per share	-64.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.96	5.67	N/A	N/A	38.21%	29.57%	25.41%	N/A
LRMR Larimar Therapeutics	-$80.60M	-$1.56	N/A	N/A	N/A	N/A	-62.92%	-53.98%	10/29/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	41.70	15.49	0.52	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.21	N/A	N/A	N/A	-13.01%	N/A	-8.00%	N/A

Latest LRMR, PAHC, XERS, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	N/A	N/A	N/A	$362.24 million	N/A
8/21/2025	Q2 2025	CVAC CureVac	-$0.15	-$0.30	-$0.15	-$0.30	$4.27 million	$1.41 million
8/14/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.47	-$0.41	+$0.06	-$0.41	N/A	N/A
8/7/2025	Q2 2025	XERS Xeris Biopharma	-$0.03	-$0.01	+$0.02	-$0.01	$64.58 million	$67.71 million
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.48%	N/A	61.54%	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Latest LRMR, PAHC, XERS, and CVAC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.05	6.17	7.64
LRMR Larimar Therapeutics	N/A	5.46	7.48
PAHC Phibro Animal Health	2.67	2.91	1.23
XERS Xeris Biopharma	N/A	1.95	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
LRMR Larimar Therapeutics	91.92%
PAHC Phibro Animal Health	99.34%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
LRMR Larimar Therapeutics	4.50%
PAHC Phibro Animal Health	50.07%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	Optionable
LRMR Larimar Therapeutics	30	82.78 million	79.05 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
XERS Xeris Biopharma	290	161.48 million	151.03 million	Optionable

LRMR, PAHC, XERS, and CVAC Headlines

Recent News About These Companies

Voss Capital LP Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS

August 21 at 6:52 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.58 Average PT from Analysts

August 20 at 2:09 AM | americanbankingnews.com

Deutsche Bank AG Grows Position in Xeris Biopharma Holdings, Inc. $XERS

August 19 at 4:01 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Rating of "Moderate Buy" by Analysts

August 18, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson Sells 107,500 Shares

August 17, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Sets New 52-Week High - Here's Why

August 17, 2025 | marketbeat.com

John Johnson Sells 107,500 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

August 16, 2025 | insidertrades.com

HC Wainwright Estimates Xeris Biopharma Q3 Earnings

August 16, 2025 | marketbeat.com

HC Wainwright Comments on Xeris Biopharma Q3 Earnings

August 16, 2025 | americanbankingnews.com

Insider Selling: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells 42,500 Shares of Stock

August 15, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Purchases 418,139 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 15, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells $309,400.00 in Stock

August 14, 2025 | insidertrades.com

Xeris Biopharma (NASDAQ:XERS) Rating Increased to Buy at HC Wainwright

August 14, 2025 | americanbankingnews.com

Xeris Biopharma's (XERS) "Buy" Rating Reaffirmed at HC Wainwright

August 13, 2025 | marketbeat.com

Informed Momentum Co LLC Grows Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 13, 2025 | marketbeat.com

Xeris Biopharma assumed with a Buy at H.C. Wainwright

August 12, 2025 | msn.com

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

August 12, 2025 | zacks.com

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

August 12, 2025 | zacks.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is Knott David M Jr's 7th Largest Position

August 12, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Raised to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Beats Expectations By $0.02 EPS

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, PAHC, XERS, and CVAC Company Descriptions

CureVac NASDAQ:CVAC

$5.44 +0.02 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$5.43 -0.01 (-0.18%)

As of 05:32 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Larimar Therapeutics NASDAQ:LRMR

$3.91 +0.22 (+5.96%)

Closing price 04:00 PM Eastern

Extended Trading

$3.89 -0.02 (-0.51%)

As of 07:32 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Phibro Animal Health NASDAQ:PAHC

$32.46 +0.91 (+2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$32.44 -0.02 (-0.05%)

As of 04:20 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Xeris Biopharma NASDAQ:XERS

$7.75 +0.16 (+2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$7.64 -0.11 (-1.35%)

As of 07:58 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time